CoChat

In vitro quality evaluation of leading brands of ciprofloxacin tablets available in Bangladesh

Open access
Uddin, Md. Sahab, Mamun, Abdullah Al, Hossain, Md. Saddam, Asaduzzaman, Md., Sarwar, Md. Shahid, Rashid, Mamunur, Herrera-Calderon, Oscar · 2017 · BMC Research Notes

The DOI matches its Crossref record; 34 of the 38 references it cites were found in a registry or an index; 2 of the 4 sources its claims cite were checked for support.

Abstract

BACKGROUND: Ciprofloxacin is a broad-spectrum antibiotic that acts against a number of bacterial infections. The study was carried out to examine the in vitro quality control tests for ten leading brands of ciprofloxacin hydrochloride 500 mg tablet formulation, registered in Bangladesh by Directorate General of Drug Administration. The quality control parameters of ten different brands of ciprofloxacin hydrochloride 500 mg tablets were determined by weight variation, friability, hardness, disintegration, dissolution and assay tests. All the tablets were evaluated for conformity with United States Pharmacopoeia-National Formulary (USP-NF) and British Pharmacopoeia (BP) standards. RESULTS: ) respectively. The disintegration time for ten brands of ciprofloxacin tablet obtained were in the subsequent order: Brand G (8.19 min) < Brand C (9.25 min) < Brand E (9.61 min) < Brand D (10.11 min) < Brand B (11.07 min) < Brand A (12.15 min) < Brand H (13.68 min) < Brand I (14.59 min) < Brand J (16.32 min) < Brand F (17.49 min). Among ten brands for dissolution test mean percentages of drug release were not less than 80% in 45 min for four tablets (Brand E, 81.52%; Brand D, 86.44%; Brand G, 86.82% and Brand C, 94.12%), consequently they met BP standard and as per USP-NF standard six brands (Brand B, 75.62%; Brand A, 76.18%; Brand E, 81.52%; Brand D, 86.44%; Brand G, 86.82% and Brand C, 94.12%) had released not less than 75% drugs, so they also complied with the standard. The percentages of the drug content of the ten brands of ciprofloxacin tablet were obtained in the following sequence: Brand H (96.84%) < Brand J (97.34%) < Brand D (98.15%) < Brand I (98.47%) < Brand E (99.37%) < Brand F (100.28%) < Brand B (100.38%) < Brand A (100.54%) < Brand G (101.39%) < Brand C (101.46%). All of the brands met the BP and USP-NF specifications for assay. First-order, Higuchi and Korsmeyer-Peppas kinetics model fit for all of the mentioned ten brands. CONCLUSION: The present study revealed that all of the leading brands of this tablet met the quality control parameters as per pharmacopoeial specifications except dissolution test for four brands (Brand J, Brand H, Brand I, and Brand F).

Overview

CoChat Summary

## TL;DR

This study tested 10 leading 500 mg ciprofloxacin tablet brands sold in Dhaka, Bangladesh using standard in vitro quality-control assays. All brands met pharmacopoeial limits for weight variation, friability, hardness, disintegration, and assay, but 4 brands failed the dissolution criterion.

## Key findings

  • Weight variation: all 10 brands complied; mean variation ranged from 1.59% (Brand C) to 3.32% (Brand E).
  • Friability: all 10 brands were below the 1% limit; mean friability ranged from 0.27% (Brand F) to 0.54% (Brand G and Brand C).
  • Hardness and disintegration: hardness ranged from 4.49 kg/cm² (Brand G) to 7.12–7.13 kg/cm² (Brand F); disintegration time ranged from 8.19 min (Brand G) to 17.49 min (Brand F), and all brands met the compendial requirement of disintegrating within 30 min.
  • Dissolution and assay: at 45 min, 6/10 brands met the USP-NF dissolution threshold of ≥75% and 4/10 met the BP threshold of ≥80%; the lowest release was 61.87% (Brand F) and the highest was 94.12% (Brand C). All brands met assay specifications, with content ranging from 96.84% (Brand H) to 101.46% (Brand C).

## Methods

  • Design/sample: laboratory-based in vitro quality evaluation of 10 commercially available ciprofloxacin hydrochloride 500 mg tablet brands, purchased from retail pharmacies in Dhaka, Bangladesh and blinded as Brands A–J.
  • Tests performed: weight variation, friability, hardness, disintegration, dissolution, and assay, using USP-NF/BP specifications as reference standards.
  • Analysis: dissolution data were analyzed with one-way ANOVA; drug-release profiles were fitted to zero-order, first-order, Higuchi, and Korsmeyer–Peppas models.

## Limitations

  • Not stated in the paper: the authors do not explicitly list study limitations.
  • Evidence from the text: the study is based on 10 brands from Dhaka retail pharmacies only, so it may not represent all ciprofloxacin products in Bangladesh.
  • Evidence from the text: the assay was done by UV spectrophotometry due to lack of instrumentation, which the paper notes instead of using HPLC.

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.1186/s13104-017-2507-y

Cites

34 of 34 references verified0 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Figures

Fig. 1 Results of weight variation test of ten leading brands of ciprofloxacin tablets. Results were expressed as mean ± SD (n = 20/brand)
Fig. 1 Results of weight variation test of ten leading brands of ciprofloxacin tablets. Results were expressed as mean ± SD (n = 20/brand)CC BY · PubMed Central
Fig. 2 Results of friability test of ten leading brands of ciprofloxacin tablets. Results were expressed as mean ± SD (n = 20/brand)
Fig. 2 Results of friability test of ten leading brands of ciprofloxacin tablets. Results were expressed as mean ± SD (n = 20/brand)CC BY · PubMed Central
Fig. 3 Results of hardness test of ten leading brands of ciprofloxacin tablets. Results were expressed as mean ± SD (n = 10/brand)
Fig. 3 Results of hardness test of ten leading brands of ciprofloxacin tablets. Results were expressed as mean ± SD (n = 10/brand)CC BY · PubMed Central
Fig. 4 Results of disintegration test of ten leading brands of ciprofloxacin tablets. Results were expressed as mean ± SD (n = 6/brand)
Fig. 4 Results of disintegration test of ten leading brands of ciprofloxacin tablets. Results were expressed as mean ± SD (n = 6/brand)CC BY · PubMed Central
Fig. 5 Standard calibration curve for ciprofloxacin hydrochloride
Fig. 5 Standard calibration curve for ciprofloxacin hydrochlorideCC BY · PubMed Central
Fig. 6 Results of dissolution profile of ten leading brands of ciprofloxacin tablets. Results were expressed as mean ± SD (n = 6/brand)
Fig. 6 Results of dissolution profile of ten leading brands of ciprofloxacin tablets. Results were expressed as mean ± SD (n = 6/brand)CC BY · PubMed Central
Fig. 7 Results of drug content of ten leading brands of ciprofloxacin tablets. Results were expressed as mean ± SD (n = 20/brand)
Fig. 7 Results of drug content of ten leading brands of ciprofloxacin tablets. Results were expressed as mean ± SD (n = 20/brand)CC BY · PubMed Central

Verification

Claims the paper makes

1 Valid · 1 Not valid · 2 Not checked · 30 Own results and interpretations

20 more claims

Create a free account to see all 34 claims and every source verdict.

See all claims — free account
  • The quote only partly states this claim. 2
  • It may state two separate claims as one. 7
  • Probably not a substantial claim. 1

Create a free account to see these claims.

Citations

Cites

Show all 34 references

Research works printed but not linked: 13

  1. Hamam HAB. Comparative in vitro evaluation of generic ciprofloxacin hydrochloride tablets. World J Pharm Pharm Sci. 2014;3(12):388–90.
  2. Hailu GS, Gutema GB, Asefaw AA, Hussen DA, Hadera MG. Comparative assessment of the physicochemical and in vitro bioavailability equivalence of cotrimoxazole tablets marketed in Tigray, Ethiopia. Int J Pharm Sci Res. 2011;2(12):3210–8.
  3. Hamilton Richard J. Tarascon pharmacopoeia. 15th ed. Burlington: Jones & Bartlett Publishers; 2014.
  4. Akpabio E, Jackson C, Ugwu C, Etim M, Udofia M. Quality control and in vitro bioequivalence studies on four brands of ciprofloxacin tablets commonly sold in Uyo Metropolis, Nigeria. J Chem Pharm Res. 2011;3(3):734–41.
  5. Tangri P, Mamgain P, Shaffi, Verma AML, Lakshmayya. In process quality control: a review. Int J Ind Pharm Bio Sci. 2012;1(1):49–51.
  6. British Pharmacopoeia Commission. British pharmacopoeia. 8th ed. Great Britain: Stationery Office; 2014.
  7. Usman S, Alam A, Suleiman R, Awad K, Abudeek I. Evaluation of dissolution testing for ciprofloxacin (500 mg) tablets: post market surveillance of different brands available in Ras Al Khaimah (UAE). Int J Biopharm. 2014;5(1):65–72.
  8. Shaikh HK, Kshirsagar RV, Patil SG. Mathematical models for drug release characterization: a review. World J Pharm Pharm Sci. 2015;4(4):324–38.
  9. Uddin MS, Mamun AA, Rashid M, Asaduzzaman M. In-process and finished products quality control tests for pharmaceutical capsules according to pharmacopoeias. Br J Pharm Res. 2016;9(2):2. · DOI
  10. Uddin MS. Quality control of pharmaceuticals: compendial standards and specifications. Germany: Scholars’ Press; 2017.
  11. Salih H, Hamam B. Comparative in vitro evaluation of generic ciprofloxacin hydrochloride tablets. World J Pharm Pharm Sci. 2014;38(12):388–96.
  12. Uduma EO, Ayodeji AA, Rosemary CA, Ogbonna O, Christian CO. Bioequivalence studies on some selected brands of ciprofloxacin hydrochloride tablets in the Nigerian market with ciproflox® as innovator brand. J App Pharm Sci. 2011;01(06):80–4.
  13. Fereja TH, Tufa SB. In vitro quality assessment and bioequivalence studies on four brands of Ciprofloxacin tablets, marketed in Ambo, Ethiopia. Int J Pharm Sci. 2015;5(2):1007–12.

Cited by

See all 32

Metadata

Authors
Uddin, M. S., Mamun, A. A., Hossain, M. S., Asaduzzaman, M., Sarwar, M. S., Rashid, M., & Herrera-Calderon, O.
Affiliations
  • Southeast University (BD)
  • Noakhali Science and Technology University (BD)
Corresponding author
Uddin, Md. Sahab
Venue
BMC Research Notes
Published
2017-05-30
Volume
10
Issue
1
Pages
185-185
ISSN
1756-0500 (ISSN-L)
OpenAlex
W2619665066
Cited by
31
References
38
Citations by year
2026: 1 · 2025: 3 · 2024: 2 · 2023: 5 · 2022: 4 · 2021: 8 · 2020: 4 · 2019: 1 · 2018: 2 · 2017: 1
FWCI
2.05
Type
journal article
Language
en
Open access
Licence
cc-by
Locations
  • BMC Research Notes (publishedVersion, cc-by)
  • Europe PMC (PubMed Central) (publishedVersion, other-oa)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
  • Greater South Information System
Funders
Southeast University
Topics
  • Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Pharmaceutical Quality and Counterfeiting
  • Physical Sciences › Chemistry › Analytical Chemistry › Analytical Methods in Pharmaceuticals
  • Social Sciences › Economics, Econometrics and Finance › Economics and Econometrics › Pharmaceutical Economics and Policy
Keywords
ciprofloxacin hydrochloride, tablets, pharmaceutical quality control, disintegration time, drug release, dissolution testing, drug content assay, weight variation, friability, tablet hardness, drug quality assessment, generic drugs, drug adulteration
MeSH terms
Anti-Bacterial Agents, Bangladesh, Chemistry, Pharmaceutical, Ciprofloxacin, Kinetics, Quality Control, Solubility, Tablets, Therapeutic Equivalency, Drug Liberation

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

The claim verdicts this report counts are experimental: their accuracy is not yet measured.

A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Cited sources are checked with a language model’s help (qwen3.8-omni-flash).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: In vitro quality evaluation of leading brands of ciprofloxacin tablets available in Bangladesh. https://app.cochat.ai/papers/10.1186/s13104-017-2507-y
The paper
Uddin, M. S., Mamun, A. A., Hossain, M. S., Asaduzzaman, M., Sarwar, M. S., Rashid, M., & Herrera-Calderon, O. (2017). In vitro quality evaluation of leading brands of ciprofloxacin tablets available in Bangladesh. BMC Research Notes. https://doi.org/10.1186/s13104-017-2507-y

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.